Japanese and American companies plan to commission clinical trials of a promising lung cancer drug developed in New Zealand.
The drug, called PR610, is part of a new class developed by scientists at the Auckland Cancer Society Research Centre and the Maurice Wilkins research centre. They preserve healthy tissue by becoming active only in the "hypoxic" parts of tumours - the zones without oxygen.
PR610 follows PR509 in being picked up for clinical development under a deal between Japanese pharmaceutical company Yakult Honsha and American biotechnology company Proacta.
Both drugs have been targeted for development in non-small-cell lung cancer that is resistant to established treatments.
They are also likely to be evaluated in treating cancers of the stomach, breast and pancreas.